What Is Mereo BioPharma Group plc (MREO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Mereo BioPharma Group plc's intrinsic value is estimated at $0.29, suggesting the stock is overvalued at its current price of $0.33. With 7 out of 8 models flagging downside (-11.1% average return), the market may be pricing in unsustainable growth. Notably, Dynamic NAV sees the most upside at +155.7% (fair value: $0.84), while First Chicago is the most conservative at -86.1% ($0.05). The spread between these extremes — +241.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MREO?
8 of 13 models are currently active for MREO. Of these, 1 model suggests upside while 7 models suggest overvaluation. The Bayesian DCF estimates MREO's intrinsic value at $0.21, implying -37.1% downside from the current price. See which stocks rank higher →
How Does MREO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, MREO ranks #205 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Mereo BioPharma Group plc operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating MREO should weigh these sector-specific dynamics alongside our model-derived fair values.
Is MREO a Value Trap?
CirclFi's Value Trap algorithm assigns MREO a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Mereo BioPharma Group plc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Mereo BioPharma Group plc's fundamental quality profile registers 5.0/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +241.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MREO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MREO's 8 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad